P&G Spinout Spins Off Another Company, While Looking To Partner Mid-Stage Oral Anemia Candidate
This article was originally published in The Pink Sheet Daily
Akebia will sell off, partner or possibly bring AKB-6548 – thought to be a safer erythropoietin stimulator than currently available injectables – through Phase III, while its spinout, Aerpio, will focus on clinical development of candidates for diabetic macular edema and inflammatory bowel disease.
You may also be interested in...
AstraZeneca To Share FibroGen’s Anemia Compound With Astellas, But Will Hoard China For Itself
In FibroGen’s FG-4592, AstraZeneca sees a potential strong seller in China where the privately held biotech's other pharma partner, Astellas, doesn’t already own rights.
AstraZeneca’s “Smart Risks” Include Sharing FibroGen’s Anemia Compound With Astellas
The British pharma continues to build its cardiovascular and metabolic pipeline to slow its dive off the patent cliff; in FibroGen’s FG-4592, it sees a potential strong seller in regions where the privately held biotech's other pharma partner, Astellas, doesn’t already own rights.
Tapping Into Top Partnering Opportunities Beyond The Blockbuster
The upcoming Therapeutic Area Partnership conference will showcase companies in niche areas that are prime targets for partnerships or acquisitions.